Drug interactions among the epidermal growth factor receptor inhibitors, other biologics and cytotoxic agents

Pharmacology and Therapeutics

Volumn 128, Issue 1, 2010, Pages 82-90

  Visentin, Michele ^a   Biason, Paola ^a   Toffoli, Giuseppe ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

Combination regimen; Drug interaction; Drug sequence; EGFR inhibitors; Pharmacodynamics; Pharmacokinetics

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CARBAMAZEPINE; CARBOPLATIN; CETUXIMAB; CIPROFLOXACIN; CISPLATIN; DOCETAXEL; ERLOTINIB; EVEROLIMUS; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GEMCITABINE; IRINOTECAN; ITRACONAZOLE; KETOCONAZOLE; LAPATINIB; METOPROLOL; NAVELBINE; OMEPRAZOLE; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; RANITIDINE; RIFAMPICIN; SORAFENIB; TOPOTECAN; TRASTUZUMAB; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CIGARETTE SMOKING; COLORECTAL CANCER; DIARRHEA; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EXCRETION; DRUG MECHANISM; DRUG METABOLISM; FOOD; HUMAN; LUNG NON SMALL CELL CANCER; METASTASIS; MONOTHERAPY; NEUTROPENIA; OUTCOME ASSESSMENT; PANCREAS CANCER; PHARMACODYNAMICS; PRIORITY JOURNAL; RASH; REVIEW; SINGLE DRUG DOSE; SURVIVAL RATE; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; BIOLOGICAL PRODUCTS; CARCINOMA; CYTOTOXINS; DRUG INTERACTIONS; HUMANS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 79955077401     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2010.05.005     Document Type: Review

References (93)

1. Adjei A.A. Novel combinations based on epidermal growth factor receptor inhibition. Clin Cancer Res 2006, 12:4446s-4450s.
2. Adjei A.A., Molina J.R., Mandrekar S.J., Marks R., Reid J.R., Croghan G., et al. Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancer. Clin Cancer Res 2007, 13:2684-2691.
3. Amado R.G., Wolf M., Peeters M., Van Cutsem E., Siena S., Freeman D.J., et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008, 26:1626-1634.
4. An J., Rettig M.B. Epidermal growth factor receptor inhibition sensitizes renal cell carcinoma cells to the cytotoxic effects of bortezomib. Mol Cancer Ther 2007, 6:61-69.
5. Azzariti A., Porcelli L., Gatti G., Nicolin A., Paradiso A. Synergic antiproliferative and antiangiogenic effects of EGFR and mTor inhibitors on pancreatic cancer cells. Biochem Pharmacol 2008, 75:1035-1044.
6. Bokemeyer C., Bondarenko I., Makhson A., Hartmann J.T., Aparicio J., de Braud F., et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009, 27:663-671.
7. Bourhis J., Rivera F., Mesia R., Awada A., Geoffrois L., Borel C., et al. Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2006, 24:2866-2872.
8. Burris H.A., Hurwitz H.I., Dees E.C., Dowlati A., Blackwell K.L., O'Neil B., et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 2005, 23:5305-5313.
9. Chau I., Cunningham D., Hickish T., Massey A., Higgins L., Osborne R., et al. Gefitinib and irinotecan in patients with fluoropyrimidine-refractory, irinotecan-naive advanced colorectal cancer: a phase I-II study. Ann Oncol 2007, 18:730-737.
10. Chun P.Y., Feng F.Y., Scheurer A.M., Davis M.A., Lawrence T.S., Nyati M.K. Synergistic effects of gemcitabine and gefitinib in the treatment of head and neck carcinoma. Cancer Res 2006, 66:981-988.
11. Ciardiello F., Bianco R., Damiano V., De Lorenzo S., Pepe S., De Placido S., et al. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin Cancer Res 1999, 5:909-916.
12. Cohen S., Carpenter G. Human epidermal growth factor: isolation and chemical and biological properties. Proc Natl Acad Sci U S A 1975, 72:1317-1321.
13. Cohen E.E., Davis D.W., Karrison T.G., Seiwert T.Y., Wong S.J., Nattam S., et al. Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. Lancet Oncol 2009, 10:247-257.
14. Cohenuram M., Saif M.W. Panitumumab the first fully human monoclonal antibody: from the bench to the clinic. Anticancer Drugs 2007, 18:7-15.
15. Cunningham D., Humblet Y., Siena S., Khayat D., Bleiberg H., Santoro A., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004, 351:337-345.
16. Delbaldo C., Pierga J.Y., Dieras V., Faivre S., Laurence V., Vedovato J.C., et al. Pharmacokinetic profile of cetuximab (erbitux) alone and in combination with irinotecan in patients with advanced EGFR-positive adenocarcinoma. Eur J Cancer 2005, 41:1739-1745.
17. Dennison S.K., Jacobs S.A., Wilson J., Seeger J., Cescon T., Raymond J.M., et al. A phase II clinical trial of ZD1839 (gefitinib) in combination with docetaxel as first-line treatment in patients with advanced breast cancer. ASCO Annual Meeting Abs. n. 1059 2007.
18. Di Leo A., Gomez H.L., Aziz Z., Zvirbule Z., Bines J., Arbushites M.C., et al. Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol 2008, 26:5544-5552.
19. Dragovich T., Huberman M., Von Hoff D.D., Rowinsky E.K., Nadler P., Wood D., et al. Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial. Cancer Chemother Pharmacol 2007, 60:295-303.
20. Dudek A.Z., Lesniewski-Kmak K., Shehadeh N.J., Pandey O.N., Franklin M., Kratzke R.A., Greeno E.W., Kumar P. Phase I study of bortezomib and cetuximab in patients with solid tumours expressing epidermal growth factor receptor. Br J Cancer 2009, 100:1379-1384.
21. Duran I., Hotte S.J., Hirte H., Chen E.X., MacLean M., Turner S., et al. Phase I targeted combination trial of sorafenib and erlotinib in patients with advanced solid tumors. Clin Cancer Res 2007, 13:4849-4857.
22. Feng F.Y., Varambally S., Tomlins S.A., Chun P.Y., Lopez C.A., Li X., et al. Role of epidermal growth factor receptor degradation in gemcitabine-mediated cytotoxicity. Oncogene 2007, 26:3431-3439.
23. Gatzemeier U., Pluzanska A., Szczesna A., Kaukel E., Roubec J., De Rosa F., et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva lung cancer investigation trial. J Clin Oncol 2007, 25:1545-1552.
24. Geyer C.E., Forster J., Lindquist D., Chan S., Romieu C.G., Pienkowski T., et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006, 355:2733-2743.
25. Giaccone G., Herbst R.S., Manegold C., Scagliotti G., Rosell R., Miller V., et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol 2004, 22:777-784.
26. Giovannetti E., Lemos C., Tekle C., Smid K., Nannizzi S., Rodriguez J.A., et al. Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells. Mol Pharmacol 2008, 73:1290-1300.
27. Hamilton M., Wolf J.L., Rusk J., Beard S.E., Clark G.M., Witt K., et al. Effects of smoking on the pharmacokinetics of erlotinib. Clin Cancer Res 2006, 12:2166-2171.
28. Hanauske A.R., Cassidy J., Sastre J., Bolling C., Jones R.J., Rakhit A., et al. Phase 1b dose escalation study of erlotinib in combination with infusional 5-fluorouracil, leucovorin, and oxaliplatin in patients with advanced solid tumors. Clin Cancer Res 2007, 13:523-531.
29. Harari P.M., Allen G.W., Bonner J.A. Biology of interactions: antiepidermal growth factor receptor agents. J Clin Oncol 2007, 25:4057-4065.
30. Harmsen S., Meijerman I., Beijnen J.H., Schellens J.H. Nuclear receptor mediated induction of cytochrome P450 3A4 by anticancer drugs: a key role for the pregnane X receptor. Cancer Chemother Pharmacol 2009, 64:35-43.
31. Hecht J., Berlin J., Malik I., Picus J., Glisson S., Kozloff M., et al. Panitumumab therapy with irinotecan, 5-fluorouracil, and leucovorin (IFL) in metastatic colorectal cancer (mCRC) patients: a pharmacokinetic (PK) analysis. Gastrointestinal Cancers Symposium. Abs. n.259 2005.
32. Hecht J.R., Mitchell E., Chidiac T., Scroggin C., Hagenstad C., Spigel D., et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 2009, 27:672-680.
33. Hecht J.R., Patnaik A., Berlin J., Venook A., Malik I., Tchekmedyian S., et al. Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. Cancer 2007, 110:980-988.
34. Herbst R.S., Giaccone G., Schiller J.H., Natale R.B., Miller V., Manegold C., et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol 2004, 22:785-794.
35. Herbst R.S., Johnson D.H., Mininberg E., Carbone D.P., Henderson T., Kim E.S., et al. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005, 23:2544-2555.
36. Herbst R.S., Prager D., Hermann R., Fehrenbacher L., Johnson B.E., Sandler A., et al. TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005, 23:5892-5899.
37. Howard L.A., Bullock K.E., Bendell J.C., Uronis H.E., Vlahovic G., Blobe G.C., et al. Bevacizumab (B) plus everolimus (E) and panitumumab (P) in refractory advanced solid tumors. ASCO Annual Meeting. Abs. n. 3551 2009.
38. Hughes A.N., O'Brien M.E., Petty W.J., Chick J.B., Rankin E., Woll P.J., et al. Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers. J Clin Oncol 2009, 27:1220-1226.
39. Hynes N.E., Lane H.A. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005, 5:341-354.
40. Johnson J.R., Cohen M., Sridhara R., Chen Y.F., Williams G.M., Duan J., et al. Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Clin Cancer Res 2005, 11:6414-6421.
41. Johnson B.E., Jackman D., Janne P.A. Rationale for a phase I trial of erlotinib and the mammalian target of rapamycin inhibitor everolimus (RAD001) for patients with relapsed non small cell lung cancer. Clin Cancer Res 2007, 13:s4628-31.
42. Jonker D.J., O'Callaghan C.J., Karapetis C.S., Zalcberg J.R., Tu D., Au H.J., et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007, 357:2040-2048.
43. Karapetis C.S., Khambata-Ford S., Jonker D.J., O'Callaghan C.J., Tu D., Tebbutt N.C., et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008, 359:1757-1765.
44. Kaseb O., Iwasaki M., Javle M., Onicescu G., Garrett-Mayer E., Abbruzzese J.L., et al. Biological activity of bevacizumab and erlotinib in patients with advanced hepatocellular carcinoma (HCC). ASCO Annual Meeting, abs. n. 4522 2009.
45. Kim E.S., Hirsh V., Mok T., Socinski M.A., Gervais R., Wu Y.L., et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008, 372:1809-1818.
46. Kim E.S., Mauer A.M., William W.N., Tran H.T., Liu D., Lee J.J., et al. A phase 2 study of cetuximab in combination with docetaxel in chemotherapy-refractory/resistant patients with advanced nonsmall cell lung cancer. Cancer 2009, 115:1713-1722.
47. Koch K.M., Reddy N.J., Cohen R.B., Lewis N.L., Whitehead B., Mackay K., et al. Effects of food on the relative bioavailability of lapatinib in cancer patients. J Clin Oncol 2009, 27:1191-1196.
48. Kris M.G., Riely G.J., Azzoli C.G., Heelan R.T., Krug L.M., Pao W., et al. Combined inhibition of mTOR and EGFR with everolimus (RAD001) and gefitinib in patients with non-small cell lung cancer who have smoked cigarettes: a phase II trial. ASCO Annual Meeting. Abs. n. 7575 2007.
49. Leggas M., Panetta J.C., Zhuang Y., Schuetz J.D., Johnston B., Bai F., et al. Gefitinib modulates the function of multiple ATP-Binding Cassette transporters in vivo. Cancer Res 2006, 66:4802-4807.
50. Li J., Brahmer J., Messersmith W., Hidalgo M., Baker S.D. Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: in vitro and in cancer patients. Invest New Drugs 2006, 24:291-297.
51. Li T., Ling Y.H., Goldman I.D., Perez-Soler R. Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells. Clin Cancer Res 2007, 13:3413-3422.
52. Li J., Zhao M., He P., Hidalgo M., Baker S.D. Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clin Cancer Res 2007, 13:3731-3737.
53. Lynch T.J., Fenton D.W., Hirsh V., Bodkin D.J., Middleman E., Chiappori A., et al. Randomized phase II study of erlotinib alone and in combination with bortezomib in previously treated advanced non-small cell lung cancer (NSCLC). ASCO Annual Meeting Proceedings Part I. 25, 18S Abs. n. 7680 2007.
54. Mahaffey C.M., Davies A.M., Lara P.N., Pryde B., Holland W., Mack P.C., et al. Schedule-dependent apoptosis in K-Ras mutant non-small-cell lung cancer cell lines treated with docetaxel and erlotinib: rationale for pharmacodynamic separation. Clin Lung Cancer 2007, 8:548-553.
55. McKillop D., Partridge E.A., Hutchison M., Rhead S.A., Parry A.C., Bardsley J., et al. Pharmacokinetics of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat and dog. Xenobiotica 2004, 34:901-915.
56. Medina P.J., Goodin S. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases. Clin Ther 2008, 30:1426-1447.
57. Mendelsohn J., Fan Z. Epidermal growth factor receptor family and chemosensitization. J Natl Cancer Inst 1997, 89:341-343.
58. Messersmith W.A., Laheru D.A., Senzer N.N., Donehower R.C., Grouleff P., Rogers T., et al. Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities. Clin Cancer Res 2004, 10:6522-6527.
59. Midgley R.S., Kerr D.J., Flaherty K.T., Stevenson J.P., Pratap S.E., Koch K.M., et al. A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecan. Ann Oncol 2007, 18:2025-2029.
60. Miller V.A., Johnson D.H., Krug L.M., Pizzo B., Tyson L., Perez W., et al. Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancer. J Clin Oncol 2003, 21:2094-2100.
61. Milton D.T., Riely G.J., Azzoli C.G., Gomez J.E., Heelan R.T., Kris M.G., et al. Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer. Cancer 2007, 110:599-605.
62. Mok T.S., Wu Y.L., Yu C.J., Zhou C., Chen Y.M., Zhang L., Ignacio J., Liao M., Srimuninnimit V., Boyer M.J., Chua-Tan M., Sriuranpong V., Sudoyo A.W., Jin K., Johnston M., Chui W., Lee J.S. Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 2009, 27:5080-5087.
63. Moore M.J., Goldstein D., Hamm J., Figer A., Hecht J.R., Gallinger S., et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada clinical trials group. J Clin Oncol 2007, 25:1960-1966.
64. Ono M., Kuwano M. Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs. Clin Cancer Res 2006, 12:7242-7251.
65. rd line therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy. ASCO Annual Meeting. Abs. n. 17039 2006.
66. Patnaik A., Wood D., Tolcher A.W., Hamilton M., Kreisberg J.I., Hammond L.A., et al. Phase I, pharmacokinetic, and biological study of erlotinib in combination with paclitaxel and carboplatin in patients with advanced solid tumors. Clin Cancer Res 2006, 12:7406-7413.
67. Peeters M., Wilson G., Ducreux M., Cervantes A., André T., Hotko Y., et al. Phase III study (20050181) of panitumumab (pmab) with FOLFIRI versus FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC): pooled safety results. ASCO Annual Meeting. Abs. n. 4064 2008.
68. Pirker R., Pereira J.R., Szczesna A., von Pawel J., Krzakowski M., Ramlau R., et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009, 373:1525-1531.
69. Prewett M.C., Hooper A.T., Bassi R., Ellis L.M., Waksal H.W., Hicklin D.J. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clin Cancer Res 2002, 8:994-1003.
70. Riely G.J., Rizvi N.A., Kris M.G., Milton D.T., Solit D.B., Rosen N., et al. Randomized phase II study of pulse erlotinib before or after carboplatin and paclitaxel in current or former smokers with advanced non-small-cell lung cancer. J Clin Oncol 2009, 27:264-270.
71. Robert F., Ezekiel M.P., Spencer S.A., Meredith R.F., Bonner J.A., Khazaeli M.B., et al. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol 2001, 19:3234-3243.
72. Rosell R., Robinet G., Szczesna A., Ramlau R., Constenla M., Mennecier B.C., et al. Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. Ann Oncol 2008, 19:362-369.
73. Rugo H.S., Franco S., Munster P., Stopeck A., Ma W., Lyandres J., et al. A phase II evaluation of lapatinib (L) and bevacizumab (B) in HER2+ metastatic breast cancer (MBC). ASCO Annual Meeting. Abs. n. 1042 2008.
74. Sharma S., Reid T., Hoosen S., Garrett C., Beck J., Davidson S., et al. Phase I study of RAD001 (everolimus), cetuximab, and irinotecan as second-line therapy in metastatic colorectal cancer (mCRC). ASCO Annual Meeting. Abs. n. e15115 2009.
75. Shimada T., Inoue K., Suzuki Y., Kawai T., Azuma E., Nakajima T., et al. Arylhydrocarbon receptor-dependent induction of liver and lung cytochromes P450 1A1, 1A2, and 1B1 by polycyclic aromatic hydrocarbons and polychlorinated biphenyls in genetically engineered C57BL/6J mice. Carcinogenesis 2002, 23:1199-1207.
76. Siegel-Lakhai W.S., Beijnen J.H., Vervenne W.L., Boot H., Keessen M., Versola M., et al. Phase I pharmacokinetic study of the safety and tolerability of lapatinib (GW572016) in combination with oxaliplatin/fluorouracil/leucovorin (FOLFOX4) in patients with solid tumors. Clin Cancer Res 2007, 13:4495-4502.
77. Siena S., Tabernero J., Burkes R.L., Cassidy J., Cunningham D., Barugel M.E., et al. Phase III study (PRIME/20050203) of panitumumab (pmab) with FOLFOX compared with FOLFOX alone in patients (pts) with previously untreated metastatic colorectal cancer (mCRC): pooled safety data. ASCO Annual Meeting. Abs. n. 4034 2008.
78. Smith D.A., Koch K.M., Arya N., Bowen C.J., Herendeen J.M., Beelen A. Effects of ketoconazole and carbamazepine on lapatinib pharmacokinetics in healthy subjects. Br J Clin Pharmacol 2009, 67:421-426.
79. Solit D.B., She Y., Lobo J., Kris M.G., Scher H.I., Rosen N., et al. Pulsatile administration of the epidermal growth factor receptor inhibitor gefitinib is significantly more effective than continuous dosing for sensitizing tumors to paclitaxel. Clin Cancer Res 2005, 11:1983-1989.
80. Swaisland H., Laight A., Stafford L., Jones H., Morris C., Dane A., et al. Pharmacokinetics and tolerability of the orally active selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in healthy volunteers. Clin Pharmacokinet 2001, 40:297-306.
81. Swaisland H.C., Ranson M., Smith R.P., Leadbetter J., Laight A., McKillop D., et al. Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol. Clin Pharmacokinet 2005, 44:1067-1081.
82. Thomas M.B., Morris J.S., Chadha R., Iwasaki M., Kaur H., Lin E., et al. Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol 2009, 27:843-850.
83. Tol J., Koopman M., Cats A., Rodenburg C.J., Creemers G.J., Schrama J.G., et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009, 360:563-572.
84. Tran H.I., Zinner R.G., Blumenschein G.R., Oh Y.W., Papadimitrakipoulou V.A., Kim E.S., et al. Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer. Invest New Drugs 2010.
85. Trarbach T., Schuette K., Stoehlmacher J., Goekkurt E., Guenther H., Ubbelohde U., et al. Dose escalating study of 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) and cetuximab in first-line therapy of patients with metastatic colorectal cancer. ASCO Annual Meeting. Abs. n. e15025 2009.
86. Trippett T.M., Herzog C., Whitlock J.A., Wolff J., Kuttesch J., Bagatell R., et al. Phase I and pharmacokinetic study of cetuximab and irinotecan in children with refractory solid tumors: a study of the pediatric oncology experimental therapeutic investigators' consortium. J Clin Oncol 2009, 27:5102-5108.
87. Twelves C., Trigo J.M., Jones R., De Rosa F., Rakhit A., Fettner S., et al. Erlotinib in combination with capecitabine and docetaxel in patients with metastatic breast cancer: a dose-escalation study. Eur J Cancer 2008, 44:419-426.
88. U.S. Food and Drug Administration (2005). Drug label iressa. labeling revision. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/.
89. U.S. Food and Drug Administration (2008). Drug label tykerb. labeling revision. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/.
90. U.S. Food and Drug Administration (2009). Drug label tarceva. labeling revision. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/.
91. Van Cutsem E., Kohne C.H., Hitre E., Zaluski J., Chang Chien C.R., Makhson A., et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009, 360:1408-1417.
92. Wagenblast J., Baghi M., Arnoldner C., Bisdas S., Gstottner W., Ackermann H., et al. Cetuximab enhances the efficacy of bortezomib in squamous cell carcinoma cell lines. J Cancer Res Clin Oncol 2009, 135:387-393.
93. Wang W., Wang E.Q., Balthasar J.P. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 2008, 84:548-558.